RFL
MaterialsRafael Holdings Inc - Class B
Live · NYSE · May 9, Close
What's Moving RFL Today?
No stock-specific AI insight has been generated for RFL yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
RFL News
14 articles- Rafael Holdings Insider Ups Holding By 1,810% During YearYahoo Finance·Apr 28, 2026
- Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”Yahoo Finance·Apr 22, 2026
- Rafael Holdings Reports Second Quarter Fiscal 2026 Financial ResultsYahoo Finance·Mar 16, 2026
- Rafael Holdings Reports First Quarter Fiscal 2026 Financial ResultsYahoo Finance·Dec 11, 2025
- One Rafael Holdings Insider Raised Stake By 1,810% In Previous YearYahoo Finance·Nov 19, 2025
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial ResultsYahoo Finance·Oct 29, 2025
- Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of DirectorsYahoo Finance·Oct 28, 2025
- Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years OldYahoo Finance·Sep 16, 2025
- Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)Yahoo Finance·Aug 27, 2025
- Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim DataYahoo Finance·Jun 18, 2025
- Rafael Holdings Up 29%, Insider Buyers Are Up 61%Yahoo Finance·Jun 12, 2025
- Rafael Holdings Reports Third Quarter Fiscal 2025 Financial ResultsYahoo Finance·Jun 11, 2025
- Rafael Holdings, Inc. Announces Final Results and Closing of Rights OfferingYahoo Finance·Jun 4, 2025
- Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™Yahoo Finance·May 20, 2025
All 14 articles loaded
Price Data
Fundamentals
Trading
About Rafael Holdings Inc - Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.